It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 Title: Longitudinal associations between mild behavioral impairment, sleep disturbance, and
- 2 progression to dementia
- 3 Author Names: Dinithi Mudalige¹, Dylan X. Guan¹, Maryam Ghahremani², Zahinoor Ismail,
- 4 MD^{3*}
- 5 (1) University of Calgary, Calgary, AB, Canada; (2) Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; (3)
- 6 Department of Psychiatry, Department of Community Health Sciences, Department of Clinical Neurosciences, Hotchkiss Brain
- 7 Institute, University of Calgary, Calgary, AB, Canada; Department of Clinical and Biomedical Sciences, Faculty of Health and
- 8 Life Sciences, University of Exeter, Exeter, UK.
- 9
- 10 Running Title: Mild behavioral impairment, sleep & dementia
- 11
- 12 *Corresponding Author:
- 13 Zahinoor Ismail
- 14 3280 Hospital Dr. NW Calgary AB
- 15 Canada T2N 4Z6
- 16 403-210-6900
- 17 <u>ismailz@ucalgary.ca</u>
- 18
- 19

20 ABSTRACT

- 21 Background: Clinical guidelines recommend incorporating non-cognitive markers like mild
- behavioral impairment (MBI) and sleep disturbance (SD) into dementia screening to improve
 detection.
- *Objective*: We investigated the longitudinal associations between MBI, SD, and incident
 dementia.
- 26 *Methods*: Participant data were from the National Alzheimer's Coordinating Center in the
- 27 United States. MBI was derived from the Neuropsychiatric Inventory Questionnaire (NPI-Q)
- using a published algorithm. SD was determined using the NPI-Q nighttime behaviors item. Cox
- 29 proportional hazard regressions with time-dependant variables for MBI, SD, and cognitive
- 30 diagnosis were used to model associations between baseline 1) MBI and incident SD (n=11277);
- 2) SD and incident MBI (n=10535); 3) MBI with concurrent SD and incident dementia
- 32 (n=13544); and 4) MBI without concurrent SD and incident dementia (n=11921). Models were
- 33 adjusted for first-visit age, sex, education, cognitive diagnosis, race, and for multiple
- 34 comparisons using the Benjamini-Hochberg method.
- 35 *Results*: The rate of developing SD was 3.1-fold higher in older adults with MBI at baseline
- compared to those without MBI (95%CI: 2.8-3.3). The rate of developing MBI was 1.5-fold
- 37 higher in older adults with baseline SD than those without SD (95%CI: 1.3-1.8). The rate of
- developing dementia was 2.2-fold greater in older adults with both MBI and SD, as opposed to
- 39 SD alone (95%CI:1.9-2.6).
- 40 *Conclusions*: There is a bidirectional relationship between MBI and SD. Older adults with SD
- 41 develop dementia at higher rates when co-occurring with MBI. Future studies should explore the
- 42 mechanisms underlying these relationships, and dementia screening may be improved by
- 43 assessing for both MBI and SD.
- 44
- 45
- 46 Keywords: Alzheimer's disease, sleep disorders, neurobehavioral manifestations, dementia,
- 47 longitudinal studies
- 48

It is made available under a CC-BY-NC-ND 4.0 International license .

49 **INTRODUCTION**

50 Dementia is currently the seventh leading cause of death worldwide, and 152 million 51 people are expected to develop dementia by 2050 [1, 2]. Alzheimer's disease (AD) is the most 52 common cause of dementia [3]. With some recent exceptions, clinical trials for AD disease-53 modifying therapies have largely been unsuccessful at meeting primary endpoints, partly because 54 of administration too late in the disease course [4]. Therefore, there is a crucial need for 55 improved detection of older adults at risk of dementia to facilitate the development of therapeutic 56 and preventative interventions and to identify those with early-stage disease potentially suitable 57 to treat with disease-modifying therapies.

58 Clinical guidelines have recommended the use of non-cognitive markers of dementia for 59 improved dementia detection [5, 6]. Two of these markers are mild behavioral impairment (MBI) 60 and sleep disturbance (SD). MBI is a neurobehavioral syndrome that captures later-life emergent 61 and persistent neuropsychiatric symptoms (NPS), representing a change from longstanding 62 behavior or personality, as a high-risk state for incident dementia [7]. MBI symptoms are 63 categorized into five domains: decreased drive and motivation (apathy), affective dysregulation 64 (mood and anxiety symptoms), impulse dyscontrol (agitation, impulsivity, abnormal reward 65 salience), social inappropriateness (impaired social cognition), and abnormal perception or 66 thought content (hallucinations and delusions, i.e., psychotic symptoms). SD can include a 67 variety of disturbances, including insomnia, REM sleep disorder, sleep apnea, and restless leg 68 syndrome, the most common of which is insomnia (i.e., difficulties falling and staying asleep), 69 resulting in excessive daytime sedation [8].

Cross-sectional studies have indicated that MBI and SD may be associated with each
other. For instance, behavioral symptoms may contribute to insomnia [9]. Conversely, SD may
increase susceptibility to behavioral symptoms [10, 11].

It is made available under a CC-BY-NC-ND 4.0 International license .

73	Both MBI and SD are associated with greater cognitive decline and dementia. First,
74	studies have indicated that MBI is associated with cognitive impairment cross-sectionally [12,
75	13] and incident cognitive decline and dementia longitudinally in cognitively normal (CN) older
76	adults [14, 15], mixed CN and mild cognitive impairment (MCI) samples [16-22] and in MCI
77	[23]. Analogous to MBI, several studies have demonstrated associations between SD and
78	cognitive decline leading to dementia [24-26]. This risk extends to the preclinical stage in CN
79	older adults, as both MBI and SD can precede typical symptoms of AD, such as memory loss,
80	and associate with a greater risk of incident dementia [15, 27]. Despite evidence suggesting that
81	both MBI and SD are associated with dementia risk, the relationship between MBI and SD and
82	their combined prognostic utility is poorly understood.
83	This study investigated bidirectional associations between MBI and SD and determined if
84	the prognostic utility of SD for incident dementia could be improved by further adding MBI to
85	the modeling. We hypothesized that older adults with MBI would develop SD at a faster rate,
86	and vice versa, due to potential positive feedback. Additionally, we hypothesized that sleep-
87	disturbed older adults with MBI would develop dementia at a faster rate than SD older adults
88	without MBI due to the additive effects of MBI and SD.
89	
90	METHOD
91	Study Design
92	The National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) was
93	used, including participant data collected approximately annually from June 2005 to May 2022.
94	The NACC was established by the National Institute on Aging and consisted of data

95 prospectively collected from 45 NIA-funded Alzheimer's Disease Research Centers (ADRCs)

96 across 26 states since 1999 [28]. Data are primarily collected by trained clinicians and clinical

97 staff from participants and informants. Extensive descriptions of NACC recruitment and data

It is made available under a CC-BY-NC-ND 4.0 International license .

collection procedures have been published elsewhere [28-31]. Participants and informants
provided informed consent at the ADRC, and the respective Institutional Review Board
approved all studies conducted at ADRCs that provided data to NACC.

101

102 Participants

103 The overall sample from the NACC-UDS consisted of 45100 participants. For this study 104 to satisfy the MBI criterion of later-life emergence of NPS [7], only participants older than 50 105 years old (n=1069) with no prior psychiatric or developmental disorders (e.g., post-traumatic 106 stress disorder (PTSD), bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive 107 disorder (OCD), Downs syndrome, Huntington's, or Parkinson's disease were included (n =108 14556). Participants missing data for demographic information (n=244) and Neuropsychiatric 109 Inventory Questionnaire (NPI-Q) domains required to derive MBI (n = 910) and SD status 110 (n=72) were excluded [Figure 1]. All participants were required to have no diagnosis of dementia 111 at baseline and have at least one follow-up visit. The clinician diagnosis in the NACC-UDS was 112 used to determine cognitive status, including dementia. 113 For the longitudinal analyses examining the association between baseline MBI status and 114 incident SD (and vice versa), additional criteria were applied, as illustrated in Figure 1. The 115 sample sizes for the analyses examining the association between baseline MBI and incident SD 116 and baseline SD and incident MBI were 11277 and 10535, respectively. The sample sizes for the 117 analyses examining the association between baseline MBI within sleep-disturbed older adults

and incident dementia and within non-sleep-disturbed older adults and incident dementia were

119 13544 and 11921, respectively.

120 Measures

121 Sleep disturbance

It is made available under a CC-BY-NC-ND 4.0 International license .

SD was measured using the NPI-Q nighttime behaviors item, as described in previous studies [32-35]. The nighttime behaviors item asks informants: "Does the patient awaken you during the night, rise too early in the morning, or take excessive naps during the day?" to which informants respond "Yes" or "No" and rate the severity of the SD on a scale of 1-3 if present. For the present study, only the reported presence or absence of SD was utilized.

127

128 Mild Behavioral Impairment

129 MBI was derived from the NPI-O [36] using a published algorithm [37, 38]. The MBI 130 decreased motivation score, with a range of 0-3, was directly derived from the NPI-O apathy 131 score. The MBI emotional dysregulation score, with a range of 0-9, was derived by summing the 132 NPI-Q depression, anxiety, and elation scores. The MBI impulse dyscontrol score, with a range 133 of 0-9, was derived by summing the NPI-Q agitation, irritability, and motor behavior scores. The 134 MBI social inappropriateness score, with a range of 0-3, was derived directly from the NPI-O 135 disinhibition score. Lastly, the MBI abnormal perception/thought content score, ranging from 0-136 6, was derived by summing the NPI-O delusions and hallucination scores. The global MBI score 137 was then derived by summing up the five domain scores for each visit, with a range of 0-30, with 138 higher scores indicating greater MBI symptom severity. However, for this study, MBI was 139 dichotomized, where a global MBI score >0 indicated presence. To meet the MBI symptom 140 persistence criterion, symptoms had to be present (global MBI score>0) at two consecutive 141 NACC visits prior to dementia onset [7].

142

143 Statistical Analysis

Participant demographics were summarized using descriptive statistics (means, standard deviations, medians, interquartile ranges, ranges, counts, and percentages). To compare between groups, Wilcoxon signed-rank tests, and chi-squared tests were used.

It is made available under a CC-BY-NC-ND 4.0 International license .

147 To determine baselines for survival models, a participant-specific baseline was generated 148 based on the first instance of symptom positivity for both MBI and SD. For each participant, the 149 baseline was set to the visit at which symptoms of either MBI or SD were endorsed to 150 correspond to the onset of behavioral symptoms or sleep disturbance. For participants who did 151 not develop MBI or SD before dementia incidence, the first study visit was considered baseline. 152 MBI positivity required two consecutive NPS+ visits consistent with the MBI symptom persistence criterion [7]. The presence of SD, however, required only a single-visit endorsement 153 154 of symptoms.

155 Survival analyses were completed utilizing Kaplan-Meier (KM) survival curves and Cox 156 proportional hazards regressions with time-dependent variables for MBI, SD, and cognitive 157 diagnosis. Four models were built for 1) the association between baseline MBI status and 158 incident SD; 2) the association between baseline SD and incident MBI; 3) the association 159 between baseline MBI with concurrent SD and incident dementia; 4) the association between 160 baseline MBI without concurrent SD and incident dementia. Participants were followed up for a 161 maximum of 16.3 years for analyses 1, 2, and 4 and 15.4 years for the third analysis; however, 162 for ease of visualization, KM curves were truncated to 12 years without omitting any data [39]. 163 Participant age at the first visit, sex, years of education, cognitive diagnosis (CN or MCI), and 164 race were included as covariates. These covariates were chosen because they are associated with 165 an increased risk for dementia [23, 40, 41]. All p-values were adjusted for multiple comparisons 166 using the Benjamini–Hochberg method to generate q-values. The proportional hazards (PH) 167 assumption of the Cox PH models was confirmed using Schoenfeld residuals. R version 4.0.5 168 was used to conduct all statistical analyses [42].

169

170 **RESULTS**

171 Participant Characteristics

It is made available under a CC-BY-NC-ND 4.0 International license .

Baseline participant demographics have been summarized in Table 1. Table 2 include participant characteristics for each model stratified by baseline MBI or SD status. In general, the four analyses had similar sample sizes, with the analysis of baseline MBI status in those without SD and incident dementia having the largest sample of 11921 participants. Across analyses, at baseline, participants were, on average, about 72 years old, had 15 years of education, and were majority female and CN (Table 1).

178

179 Analysis 1: Association Between Baseline MBI and Incident Sleep Disturbance

180 Of the total sample (n=11277), 6658 (59.0%) were female, with a mean first-visit age of

181 72.7 years (*SD*=8.8, range=50-104), and mean 15.7 (*SD*=3.1, range=0-29) years of education. Of

182 this sample, 8579 (76.1%) were CN, 2698 (23.9%) had MCI, and 8721 (77.3%) were White. A

total of 1562 (13.9%) participants had MBI, and 9715 (86.1%) had no MBI. The MBI group

184 comprised significantly more males and those with MCI [Table 2].

185 Over the total follow-up period of 4.8 (SD=3.6, range=0.4-16.3) years, 2467 (21.9%)

186 individuals developed SD before dementia. KM survival curves at a median follow-up time of 6

187 years showed that sleep-disturbance-free survival in the no MBI group was 75.5% (95%CI:74.3-

188 76.6) and in the MBI group was 47.7% (95% CI:44.1-51.5) [Figure 2]. Cox proportional hazards

regressions showed that the MBI group had a 3.0-fold (95%CI:2.8-3.3, q<0.001) greater rate of

190 developing SD relative to those without MBI [Table 3].

191

192 Analysis 2: Association Between Baseline Sleep Disturbance and Incident MBI

193 Of the total sample (n=10535), 6412 (60.9%) were female, with a mean first-visit age of

194 72.7 (SD=8.8, range=50-101) years, and mean 15.7 (SD=3.2, range=0-29) years of education. Of

195 this sample, 8375 (79.5%) were CN, 2160 (20.5%) had MCI, and 8063 (76.5%) were White. A

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296033; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- total of 820 (7.8%) participants had SD, and 9715 (92.2%) had no SD. The SD group comprised
- 197 significantly more females and CN individuals [Table 2].
- 198 Over the total follow-up period of 4.9 (SD=3.6, range=0.4-16.3), 1504 (14.3%)
- 199 individuals developed MBI. KM survival curves at a median follow-up time of 6 years showed
- that MBI-free survival in the no SD group was_81.6% (95%CI:80.5-82.6) and in the SD group,
- 201 was 74.3% (95%CI:70.2-78.7) [Figure 2]. Cox proportional hazards regressions showed that
- 202 participants with SD at baseline had a 1.5-fold (95%CI:1.3-1.8, q<0.001) greater rate of
- 203 developing MBI than those without SD [Table 3].
- 204

205 Analysis 3: Association Between Baseline Sleep Disturbance and Incident Dementia, stratified 206 by MBI status

207 Of the total sample (n=1567), 785 (50.1%) were female, with a mean first-visit age of

208 72.2 (SD=8.8, range=50-101) years and a mean 15.4 (SD=3.3, range=0-30) years of education.

209 Of this sample, 797 (50.9%) were CN, 770 (49.1%) had MCI, and 1260 (80.4%) were White. Of

210 the sample, 707 (45.1) individuals had MBI at baseline, and 860 (54.9) had no MBI at baseline.

211 On average, participants with MBI were more likely to be male and have MCI [Table 2].

Over the average total follow-up period of 4.2 (SD=3.3, range=0.4-15.4) years, 411

213 (26.2%) individuals developed dementia. In those with SD, KM survival curves out to 6 years

- showed that dementia-free survival in the no MBI group was 79.6% (95% CI:76.0-83.4) and in
- 215 the MBI group, was 43.7% (38.7-49.4) [Figure 2].
- 216 Cox proportional hazards regressions showed that sleep-disturbed older adults with MBI

had a 2.2-fold (95%CI:1.9-2.6; q<0.001) greater rate of developing dementia compared to sleep-

218 disturbed older adults without MBI [Table 3].

It is made available under a CC-BY-NC-ND 4.0 International license .

220 Analysis 4: Association Between No Baseline Sleep Disturbance and Incident Dementia,

- 221 stratified by MBI status
- 222 Of the total sample (n=11921), 6991 (50.1%) were female, with a mean first-visit age of 223 72.9 (SD=8.8, range=50-104) years and a mean 15.7 (SD=3.1, range=0-29) years of education. 224 Of this sample, 8628 (72.4%) were CN, 3293 27.6%) had MCI, and 9269 (77.8%) were White. 225 Of the sample, 1902 (16.0) individuals had MBI at baseline, and 10019 (84.0) had no MBI at 226 baseline. On average, participants with MBI were more likely to be male and have MCI [Table 227 2]. 228 Over the average total follow-up period of 5.0 (SD=3.6, range=0.4-16.3) years, 1959 229 (16.4%) individuals developed dementia. In those without SD, KM survival curves out to 6 years 230 showed that dementia-free survival in the no MBI group was 85.6% (95% CI:84.7-86.5) and in 231 the MBI group was 51.8% (48.8-54.9) [Figure 2]. 232 Cox proportional hazards regressions showed that non-sleep-disturbed older adults with 233 MBI had a 1.9-fold (95%CI:1.8-2.0; q<0.001) greater rate of developing dementia compared to 234 non-sleep-disturbed older adults without MBI [Table 3].
- 235

236 **DISCUSSION**

This study aimed to investigate the longitudinal associations between MBI and SD and explore the SD-associated risk for incident dementia in those with and without comorbid MBI. As hypothesized, this study demonstrated a bidirectional longitudinal relationship between MBI and SD; older adults with MBI at baseline developed SD at a greater rate than those without MBI, and those with SD at baseline developed MBI at a greater rate than those without SD. Furthermore, individuals concurrently reporting both SD and MBI and individuals experiencing only MBI developed dementia at faster rates than those with only SD or no SD, respectively.

It is made available under a CC-BY-NC-ND 4.0 International license .

This indicates that there may be additive effects of MBI and SD when considering the risk to dementia.

246 Previous literature has cross-sectionally linked certain NPS to SD. One study found the 247 presence of depression, disinhibition, and aberrant motor behavior to be associated with a greater 248 frequency and severity of SD [43]. This finding may be explained by the difficulties these 249 behavioral symptoms pose when attempting to fall asleep and stay asleep. Those experiencing 250 depression have impaired sleep continuity with frequent and long periods of wakefulness, 251 reduced sleep efficiency, delayed sleep onset, and a reduced total sleep time [9]. SD in 252 behaviorally disturbed individuals may arise from a disruption of the homeostatic and circadian 253 drives to sleep [44]. The reverse relationship has also been postulated, where SD may increase 254 susceptibility to behavioral symptoms such as anxiety and depression [10], poor emotional 255 generation and regulation [45], and decreased inhibition [11]. This association may be due to 256 functional connectivity deficits between the amygdala and the ventral anterior cingulate cortex 257 (vACC) [46], leading to enhanced amygdala responses to negative stimuli, causing increased 258 aggression and agitation. Sleep deficiencies can also reduce the ability of the medial prefrontal 259 cortex (mPFC) to inhibit amygdala activity, which, similarly, may lead to behavioral and 260 emotional instability [47, 48]. Thus, in line with previous literature, the findings of the present 261 study indicate a possible bidirectional relationship between SD and behavioral impairments, such 262 that behavioral symptoms may lead to the development of SD and vice versa.

SD as a risk factor can contribute to underlying AD pathology [49-51] but may also be sequelae of existing AD pathology in older adults (Ju et al., 2014). Hence, the bidirectional association between MBI and SD and a higher rate of decline to dementia with both MBI and SD may be explained by a common pathology. Having MBI may indicate a more advanced pathology, which is more likely to disrupt regions of the brain that regulate sleep, leading to SD [16, 52-59]. Alternatively, a positive feedback mechanism may be in play such that increased SD

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296033; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

269 contributes to MBI, and MBI contributes to SD. In such a scenario, therapies aimed at alleviating 270 MBI symptoms may help reduce the development or exacerbation of SD, as the reduction of 271 behavioral symptoms may increase the likelihood of falling asleep and staying asleep. 272 Conversely, existing medications for the management of SD may help directly or indirectly 273 reduce behavioral symptoms such as anxiety and depression [60]. 274 Additionally, these results are consistent with previous studies that have established the 275 association between MBI, sleep, and dementia [24, 26, 49]. First, MBI has been linked to 276 incident cognitive decline and dementia [61]. The greater dementia risk in those with MBI may 277 relate to the association of MBI with pathological hallmarks of AD, like the formation of 278 amyloid- β (A β) plaques and hyperphosphorylation and aggregation of tau proteins [62]. Studies 279 have shown MBI to be associated with A β accumulation [56, 63-65] and hyperphosphorylated 280 tau deposition [66, 67]. Second, studies have found that in non-dementia older adults, those with 281 SD have a greater risk of developing dementia (Lee et al., 2020; Robbins et al., 2021; Shi et al., 282 2018). Sleep-wake cycles influence A β levels in the brain, where decreased sleep leads to A β 283 accumulation [49-51]. The formation of A β plaques is proposed to decrease sleep quality directly 284 by disrupting neuronal function in brain regions involved in sleep-wake cycles [68] or indirectly, 285 worsening the effects in a positive-feedback manner [49]. Studies have also found that tau 286 accumulation increases with greater SD and vice versa [69]. In light of the association between 287 MBI and SD with greater cognitive decline and incident dementia due to similar pathological 288 changes, combining the markers may enhance the ability to detect or predict dementia onset. 289 Based on these findings, clinicians might consider screening for SD and further assess 290 MBI presence to improve dementia risk assessment in their patients. Several studies suggest that 291 combining markers of dementia, such as cognition, gait, and MBI, may improve dementia 292 prognostication [70, 71]. Thus, these markers should be incorporated into dementia risk 293 assessments to best aid early detection.

It is made available under a CC-BY-NC-ND 4.0 International license .

294 This study does have limitations. Using a single item from the NPI-Q to assess SD, rated 295 by an informant, may not identify all presentations of SD, as it captures insomnia and excessive 296 daytime sedation (EDS). While EDS is a symptom of a variety of SD [72], it is important to 297 assess this relationship, specifically examining SD such as REM sleep disorder, sleep apnea, and 298 restless leg syndrome. This will allow for a more complete understating of the impact of SD on 299 incident dementia, especially as SD, such as REM sleep disorder, are associated with specific 300 dementias like Lewy body dementia [73]. Additionally, the use of NPI-Q to derive MBI scores 301 poses a potential limitation as this questionnaire was not designed initially to measure MBI. For 302 instance, the two-consecutive visits method was used to operationalize MBI because the NPI-O 303 has a one-month reference range. However, because symptom presence between study visits 304 outside of the reference range of the NPI-Q cannot be confirmed, the symptom persistence 305 criteria required for MBI diagnosis might not be met. The MBI checklist (MBI-C) was 306 specifically developed for the detection of MBI, has a 6-month reference range, and explicitly 307 captures later-life emergent and persistent NPS [7, 74]. However, the MBI-C has only very 308 recently been included in the NACC UDS as an optional measure, so it will take some time to 309 generate sufficient data with this scale. Therefore, in legacy datasets, using operational 310 definitions or algorithms to derive MBI status from other measures is necessary. Dichotomizing 311 SD and MBI did not allow for the assessment of the severity of these items, which may have 312 provided additional insights. Nonetheless, we did find significant associations with discrete 313 variables. Future studies could explore this relationship with more robust and continuous 314 indicators of MBI and SD to ascertain whether this relationship holds when the severity of 315 symptoms is considered. Lastly, we acknowledge there are other variables, in addition to the 316 covariates used in this study, that could impact the relationships investigated in this study. 317 Therefore, future studies should investigate how other variables associated with increased

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296033; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

318 dementia risk, such as obesity, type 2 diabetes, traumatic brain injury, stroke, and hearing loss,

319 impact these relationships [75].

320	Regardless, this study establishes a starting point for further investigations regarding the
321	bidirectional relationship between MBI and SD, the relationship between SD and dementia, and
322	MBI and dementia. Additionally, by illustrating the bidirectional relationship and the
323	relationship with incident dementia, this study emphasizes the importance of non-cognitive
324	markers of dementia in pre-dementia screening, especially the importance of SD. Being
325	longitudinal in design, this study allowed exploration of the bidirectional relationship between
326	MBI and SD. The large sample size also provided sufficient statistical power to test several
327	hypotheses, enabling a fuller understanding of the relationship between MBI, SD, and dementia.
328	CONCLUSION
329	This study demonstrated that older adults with MBI have a greater rate of incident SD,
330	and those with SD have a greater incidence of MBI. Furthermore, when participants experienced
331	SD along with MBI, the rate of developing dementia was greater compared to experiencing only
332	SD. These findings set the stage for treatment studies to determine if treating symptoms of MBI
333	could reduce the incidence of SD and vice versa, as well as the impact of treating both on
334	incident cognitive decline and dementia. Nonetheless, both sleep and MBI should be
335	incorporated into dementia risk assessments to aid with early detection.
336	
337	
338	
339	
340	
341	
342	

It is made available under a CC-BY-NC-ND 4.0 International license .

343 ACKNOWLEDGEMENTS

- 344 The authors have no acknowledgments to report.
- 345

346 FUNDING

- Dinithi Mudalige received funding from Alberta Innovates as part of the 2022 Summer
 Student Award and the Provincial Seniors Health and Continuing Care Studentship as
 part of the 2023 Summer Student Award; Alberta Innovates and Seniors Health played no
 role in any part of the study design, analysis, or interpretation of this study.
- Zahinoor Ismail is funded by the Canadian Institutes of Health Research (BCA2633) and
 the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research
 Centre. The views expressed are those of the author(s) and not necessarily those of the
 NIHR or the Department of Health and Social Care.
- The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are
 contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD),
 P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD),
 P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30
 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30
 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30
 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30
- 362 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30

363 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI David Bennett, MD), P30

- 364 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30
- 365 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD),
- 366 P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30
- 367 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30
- 368 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow,
- 369 MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen
- 370 Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30
- 371 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30
- 372 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20
- 373 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20
- AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30
- 375 AG072959 (PI James Leverenz, MD).

It is made available under a CC-BY-NC-ND 4.0 International license .

376 CONFLICT OF INTEREST

- 377 ZI reports serving as a consultant/advisor to Eisai, Lundbeck, Otsuka, and Roche. All authors
- 378 have no conflict of interest to report.
- 379

380 DATA AVAILABILITY

- 381 The data used in this study were obtained from NACC (https://naccdata.org/). Data are available
- 382 free of charge to bona fide researchers who submit a research proposal.
- 383

385

384 **REFERENCES**

- Lynch C (2020) World Alzheimer Report 2019: Attitudes to dementia, a global survey:
 Public health: Engaging people in ADRD research. *Alzheimer's & Dementia* 16, e038255.
- 388[2]World Health Organization (2021) Global status report on the public health response to
dementia.
- 390 [3] Morris JC (1996) Classification of dementia and Alzheimer's disease. *Acta Neurologica* 391 *Scandinavica* 94, 41-50.
- Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton
 LT (2016) Why has therapy development for dementia failed in the last two decades? *Alzheimer's & Dementia* 12, 60-64.
- Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce Jr R, MonteroOdasso M, Rockwood K, Rosa-Neto P, Seitz D (2020) Recommendations of the 5th
 Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimer's & Dementia* 16, 1182-1195.
- Montero-Odasso M, Pieruccini-Faria F, Ismail Z, Li K, Lim A, Phillips N, Kamkar N,
 Sarquis-Adamson Y, Speechley M, Theou O, Verghese J, Wallace L, Camicioli R (2020)
 CCCDTD5 recommendations on early non cognitive markers of dementia: A Canadian
 consensus. *Alzheimers Dement (N Y)* 6, e12068.
- Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, Agüera-Ortiz L, Sweet R,
 Miller D, Lyketsos CG (2016) Neuropsychiatric symptoms as early manifestations of
 emergent dementia: provisional diagnostic criteria for mild behavioral impairment. *Alzheimer's & Dementia* 12, 195-202.
- 407 [8] Miner B, Kryger MH (2017) Sleep in the Aging Population. *Sleep Med Clin* **12**, 31-38.
- 408 [9] Nutt D, Wilson S, Paterson L (2008) Sleep disorders as core symptoms of depression.
 409 *Dialogues Clin Neurosci* 10, 329-336.
- [10] Babson KA, Trainor CD, Feldner MT, Blumenthal H (2010) A test of the effects of acute
 sleep deprivation on general and specific self-reported anxiety and depressive symptoms:
 An experimental extension. *Journal of Behavior Therapy and Experimental Psychiatry*413 41, 297-303.
- 414 [11] Drummond SPA, Paulus MP, Tapert SF (2006) Effects of two nights sleep deprivation
 415 and two nights recovery sleep on response inhibition. *Journal of Sleep Research* 15, 261416 265.
- 417 [12] Rouse HJ, Small BJ, Schinka JA, Loewenstein DA, Duara R, Potter H (2021) Mild
 418 behavioral impairment as a predictor of cognitive functioning in older adults. *Int*419 *Psychogeriatr* 33, 285-293.

420	[13]	Kassam F, Chen H, Nosheny RL, McGirr A, Williams T, Ng N, Camacho M, Mackin
420	[13]	RS, Weiner MW, Ismail Z (2022) Cognitive profile of people with mild behavioral
422		impairment in Brain Health Registry participants. <i>International Psychogeriatrics</i> , 1-10.
423	[14]	Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, Megalogeni M,
424	[1.]	Corbett A, Aarsland D, Ballard C (2019) Mild behavioral impairment as a marker of
425		cognitive decline in cognitively normal older adults. The American Journal of Geriatric
426		<i>Psychiatry</i> 27 , 823-834.
427	[15]	Ismail Z, McGirr A, Gill S, Hu S, Forkert ND, Smith EE (2021) Mild Behavioral
428		Impairment and Subjective Cognitive Decline Predict Cognitive and Functional Decline.
429		<i>J Alzheimers Dis</i> 80 , 459-469.
430	[16]	Ghahremani M, Nathan S, Smith EE, McGirr A, Goodyear B, Ismail Z (2023) Functional
431		connectivity and mild behavioral impairment in dementia-free elderly. Alzheimer's &
432		Dementia: Translational Research & Clinical Interventions 9, e12371.
433	[17]	Matsuoka T, Ismail Z, Narumoto J (2019) Prevalence of Mild Behavioral Impairment and
434	54.03	Risk of Dementia in a Psychiatric Outpatient Clinic.
435	[18]	Kan CN, Cano J, Zhao X, Ismail Z, Chen CL, Xu X (2022) Prevalence, Clinical
436		Correlates, Cognitive Trajectories, and Dementia Risk Associated With Mild Behavioral
437	[10]	Impairment in Asians. J Clin Psychiatry 83. Walfard K. Crassa P. Asiand D. Israell 7. Carbett A. Ballard C. Harrashira A.
438 439	[19]	Wolfova K, Creese B, Aarsland D, Ismail Z, Corbett A, Ballard C, Hampshire A, Cermakova P (2022) Gender/Sex Differences in the Association of Mild Behavioral
440		Impairment with Cognitive Aging. J Alzheimers Dis 88, 345-355.
441	[20]	Vellone D, Ghahremani M, Goodarzi Z, Forkert ND, Smith EE, Ismail Z (2022) Apathy
442	[20]	and APOE in mild behavioral impairment, and risk for incident dementia. <i>Alzheimers</i>
443		Dement (N Y) 8 , e12370.
444	[21]	Ebrahim IM, Ghahremani M, Camicioli R, Smith EE, Ismail Z (2023) Effects of race,
445		baseline cognition, and APOE on the association of affective dysregulation with incident
446		dementia: A longitudinal study of dementia-free older adults. Journal of Affective
447		<i>Disorders</i> 332 , 9-18.
448	[22]	Ismail Z, Ghahremani M, Amlish Munir M, Fischer CE, Smith EE, Creese B (2023) A
449		longitudinal study of late-life psychosis and incident dementia and the potential effects of
450		race and cognition. Nature Mental Health 1, 273-283.
451	[23]	McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z (2022) Progression to
452		Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function
453	[0.4]	of Late-Onset Neuropsychiatric Symptoms. <i>Neurology</i> 98 , e2132.
454	[24]	Shi L, Chen S-J, Ma M-Y, Bao Y-P, Han Y, Wang Y-M, Shi J, Vitiello MV, Lu L (2018)
455 456		Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis.
450 457	[25]	Sleep medicine reviews 40, 4-16. Robbins R, Quan SF, Weaver MD, Bormes G, Barger LK, Czeisler CA (2021)
458	[23]	Examining sleep deficiency and disturbance and their risk for incident dementia and all-
459		cause mortality in older adults across 5 years in the United States. <i>Aging (Albany NY)</i> 13,
460		3254-3268.
461	[26]	Lee W, Gray SL, Barthold D, Maust DT, Marcum ZA (2020) Association Between
462	[=0]	Informant-Reported Sleep Disturbance and Incident Dementia: An Analysis of the
463		National Alzheimer's Coordinating Center Uniform Data Set. Journal of Applied
464		Gerontology 41 , 285-294.
465	[27]	Sterniczuk R, Theou O, Rusak B, Rockwood K (2013) Sleep disturbance is associated
466	_	with incident dementia and mortality. Current Alzheimer research 10, 767-775.

467	[28]	Beekly DL, Ramos EM, van Belle G, Deitrich W, Clark AD, Jacka ME, Kukull WA
468		(2004) The national Alzheimer's coordinating center (NACC) database: an Alzheimer
469 470	[20]	disease database. Alzheimer Disease & Associated Disorders 18, 270-277.
470	[29]	Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, Jicha G, Carlsson
471 472		C, Burns J, Quinn J (2018) Version 3 of the National Alzheimer's Coordinating Center's
472	[20]	uniform data set. <i>Alzheimer disease and associated disorders</i> . Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, Foster NL, Galasko
474	[30]	D, Graff-Radford N, Peskind ER (2006) The Uniform Data Set (UDS): clinical and
475		cognitive variables and descriptive data from Alzheimer Disease Centers. <i>Alzheimer</i>
476		Disease & Associated Disorders 20, 210-216.
477	[31]	Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J,
478	[31]	DeCarli C, Foster NL, Galasko D (2009) The Alzheimer's disease centers' uniform data
479		set (UDS): The neuropsychological test battery. <i>Alzheimer disease and associated</i>
480		disorders 23, 91.
481	[32]	Bliwise DL, Mercaldo ND, Avidan AY, Boeve BF, Greer SA, Kukull WA (2011) Sleep
482	[52]	disturbance in dementia with Lewy bodies and Alzheimer's disease: a multicenter
483		analysis. Dementia and geriatric cognitive disorders 31 , 239-246.
484	[33]	Bubu OM, Williams ET, Umasabor-Bubu OQ, Kaur SS, Turner AD, Blanc J, Cejudo JR,
485		Mullins AE, Parekh A, Kam K (2021) Interactive Associations of Neuropsychiatry
486		Inventory-Questionnaire Assessed Sleep Disturbance and Vascular Risk on Alzheimer's
487		Disease Stage Progression in Clinically Normal Older Adults. Frontiers in Aging
488		Neuroscience 13.
489	[34]	Burke SL, Hu T, Spadola CE, Burgess A, Li T, Cadet T (2018) Treatment of Sleep
490		Disturbance May Reduce the Risk of Future Probable Alzheimer's Disease. Journal of
491		<i>Aging and Health</i> 31 , 322-342.
492	[35]	Burke SL, Hu T, Spadola CE, Li T, Naseh M, Burgess A, Cadet T (2018) Mild cognitive
493		impairment: associations with sleep disturbance, apolipoprotein e4, and sleep
494		medications. Sleep Medicine 52, 168-176.
495	[36]	Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL,
496		DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the
497		Neuropsychiatric Inventory. <i>The Journal of neuropsychiatry and clinical neurosciences</i>
498	[27]	12 , 233-239.
499 500	[37]	Sheikh F, Ismail Z, Mortby ME, Barber P, Cieslak A, Fischer K, Granger R, Hogan DB,
500		Mackie A, Maxwell CJ (2018) Prevalence of mild behavioral impairment in mild
501 502		cognitive impairment and subjective cognitive decline, and its association with caregiver burden. <i>International Psychogeriatrics</i> 30 , 233-244.
502 503	[38]	Mortby ME, Ismail Z, Anstey KJ (2018) Prevalence estimates of mild behavioral
505	[30]	impairment in a population-based sample of pre-dementia states and cognitively healthy
505		older adults. <i>Int Psychogeriatr</i> 30 , 221-232.
506	[39]	Pocock SJ, Clayton TC, Altman DG (2002) Survival plots of time-to-event outcomes in
507	[37]	clinical trials: good practice and pitfalls. <i>Lancet</i> 359 , 1686-1689.
508	[40]	Lee M, Whitsel E, Avery C, Hughes TM, Griswold ME, Sedaghat S, Gottesman RF,
509	[]	Mosley TH, Heiss G, Lutsey PL (2022) Variation in Population Attributable Fraction of
510		Dementia Associated With Potentially Modifiable Risk Factors by Race and Ethnicity in
511		the US. JAMA Network Open 5, e2219672-e2219672.
512	[41]	Chen J-H, Lin K-P, Chen Y-C (2009) Risk factors for dementia. Journal of the Formosan
513		Medical Association 108, 754-764.
514	[42]	R Core Team (2022), ed. Computing RFfS, Austria.

515	[43]	García-Alberca JM, Lara JP, Cruz B, Garrido V, Gris E, Barbancho MÁ (2013) Sleep
516		disturbances in Alzheimer's disease are associated with neuropsychiatric symptoms and
517		antidementia treatment. The Journal of nervous and mental disease 201, 251-257.
518	[44]	Borbély AA (1982) A two process model of sleep regulation. Hum neurobiol 1, 195-204.
519	[45]	Palmer CA, Alfano CA (2017) Sleep and emotion regulation: An organizing, integrative
520	[10]	review. Sleep Medicine Reviews 31 , 6-16.
521	[46]	Motomura Y, Kitamura S, Oba K, Terasawa Y, Enomoto M, Katayose Y, Hida A,
	[40]	•
522		Moriguchi Y, Higuchi S, Mishima K (2013) Sleep debt elicits negative emotional
523		reaction through diminished amygdala-anterior cingulate functional connectivity. <i>PloS</i>
524		one 8 , e56578.
525	[47]	Motomura Y, Katsunuma R, Yoshimura M, Mishima K (2017) Two days' sleep debt
526		causes mood decline during resting state via diminished amygdala-prefrontal
527		connectivity. Sleep 40.
528	[48]	Ismail Z, Herrmann N, Francis PL, Rothenburg LS, Lobaugh NJ, Leibovitch FS, Black
529		SE, Lanctôt KL (2009) A SPECT Study of Sleep Disturbance and Alzheimer's Disease.
530		Dementia and Geriatric Cognitive Disorders 27, 254-259.
531	[49]	Ju Y-ES, Lucey BP, Holtzman DM (2014) Sleep and Alzheimer disease pathologya
532		bidirectional relationship. Nature reviews. Neurology 10, 115-119.
533	[50]	Winer JR, Mander BA, Kumar S, Reed M, Baker SL, Jagust WJ, Walker MP (2020)
534	[20]	Sleep Disturbance Forecasts β-Amyloid Accumulation across Subsequent Years. <i>Current</i>
535		Biology 30, 4291-4298.e4293.
	[51]	
536	[51]	Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S,
537		Holtzman DM (2009) Amyloid- β dynamics are regulated by orexin and the sleep-wake
538		cycle. <i>Science</i> 326 , 1005-1007.
539	[52]	Matsuoka T, Imai A, Narumoto J (2023) Neuroimaging of mild behavioral impairment: A
540		systematic review. Psychiatry and Clinical Neurosciences Reports 2, e81.
541	[53]	Matuskova V, Ismail Z, Nikolai T, Markova H, Cechova K, Nedelska Z, Laczó J, Wang
542		M, Hort J, Vyhnalek M (2021) Mild Behavioral Impairment Is Associated With Atrophy
543		of Entorhinal Cortex and Hippocampus in a Memory Clinic Cohort. Front Aging
544		<i>Neurosci</i> 13 , 643271.
545	[54]	Creese B, Arathimos R, Brooker H, Aarsland D, Corbett A, Lewis C, Ballard C, Ismail Z
546		(2021) Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment
547		in healthy older adults. Alzheimer's & Dementia: Diagnosis, Assessment & Disease
548		<i>Monitoring</i> 13 , e12164.
549	[55]	Miao R, Chen HY, Robert P, Smith EE, Ismail Z (2021) White matter hyperintensities
550	[30]	and mild behavioral impairment: Findings from the MEMENTO cohort study. <i>Cereb</i>
551		Circ Cogn Behav 2, 100028.
552	[56]	Miao R, Chen HY, Gill S, Naude J, Smith EE, Ismail Z (2022) Plasma β-Amyloid in
	[30]	Mild Behavioural Impairment - Neuropsychiatric Symptoms on the Alzheimer's
553		
554	[]	Continuum. J Geriatr Psychiatry Neurol 35 , 434-441.
555	[57]	Naude JP, Gill S, Hu S, McGirr A, Forkert ND, Monchi O, Stys PK, Smith EE, Ismail Z,
556		Initiative AsDN (2020) Plasma neurofilament light: a marker of neurodegeneration in
557		mild behavioral impairment. Journal of Alzheimer's disease 76, 1017-1027.
558	[58]	Shu J, Qiang Q, Yan Y, Wen Y, Ren Y, Wei W, Zhang L (2021) Distinct patterns of
559		brain atrophy associated with mild behavioral impairment in cognitively normal elderly
560		adults. International Journal of Medical Sciences 18, 2950.
561	[59]	Gill S, Wang M, Mouches P, Rajashekar D, Sajobi T, MacMaster FP, Smith EE, Forkert
562		ND, Ismail Z (2021) Neural correlates of the impulse dyscontrol domain of mild
563		behavioral impairment. Int J Geriatr Psychiatry 36, 1398-1406.

564	[60]	Krystal AD (2020) Sleep therapeutics and neuropsychiatric illness.
565	5643	Neuropsychopharmacology 45, 166-175.
566	[61]	Creese B, Ismail Z (2022) Mild behavioral impairment: measurement and clinical
567		correlates of a novel marker of preclinical Alzheimer's disease. Alzheimers Res Ther 14,
568		2.
569	[62]	Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM,
570		Vemuri P, Wiste HJ, Weigand SD (2013) Update on hypothetical model of Alzheimer's
571		disease biomarkers. Lancet neurology 12, 207.
572	[63]	Sun Y, Xu W, Chen K-L, Shen X-N, Tan L, Yu J-T, for the Alzheimer's Disease
573		Neuroimaging I (2021) Mild behavioral impairment correlates of cognitive impairments
574		in older adults without dementia: mediation by amyloid pathology. Translational
575		Psychiatry 11, 577.
576	[64]	Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, Kang MS,
577		Mathotaarachchi S, Benedet AL, Parsons M, Qureshi MNI, Thomas É M, Shin M, Dion
578		LA, Massarweh G, Soucy JP, Tsai IH, Vitali P, Ismail Z, Rosa-Neto P, Gauthier S (2020)
579		Mild behavioral impairment is associated with β -amyloid but not tau or
580		neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement 16, 192-
581		199.
582	[65]	Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE (2023) Optimizing detection
583		of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild
584		behavioral impairment in ADNI and MEMENTO. Mol Neurodegener in press.
585	[66]	Johansson M, Stomrud E, Insel PS, Leuzy A, Johansson PM, Smith R, Ismail Z,
586	L J	Janelidze S, Palmqvist S, van Westen D, Mattsson-Carlgren N, Hansson O (2021) Mild
587		behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease.
588		Transl Psychiatry 11, 76.
589	[67]	Ghahremani M, Wang M, Chen H-Y, Zetterberg H, Smith E, Ismail Z, Initiative AsDN
590	[.,]	(2023) Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in
591		Preclinical and Prodromal Alzheimer Disease. <i>Neurology</i> 100 , e683-e693.
592	[68]	Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta
593	[00]	neuropathologica 82, 239-259.
594	[69]	Wang C, Holtzman DM (2020) Bidirectional relationship between sleep and Alzheimer's
595	[0]]	disease: role of amyloid, tau, and other factors. <i>Neuropsychopharmacology</i> 45 , 104-120.
596	[70]	Verghese J, Wang C, Lipton RB, Holtzer R (2013) Motoric cognitive risk syndrome and
597	[,0]	the risk of dementia. J Gerontol A Biol Sci Med Sci 68, 412-418.
598	[71]	Guan DX, Chen H-Y, Camicioli R, Montero-Odasso M, Smith EE, Ismail Z (2022) Dual-
599	[,]	task gait and mild behavioral impairment: The interface between non-cognitive dementia
600		markers. <i>Experimental Gerontology</i> 162 , 111743.
601	[72]	Brown J, Makker HK (2020) An approach to excessive daytime sleepiness in adults. <i>BMJ</i>
602	[/2]	368 .
603	[73]	Boeve BF (2019) REM sleep behavior disorder associated with dementia with Lewy
604	[/5]	bodies. Rapid-eye-movement sleep behavior disorder, 67-76.
605	[74]	Hu S, Patten S, Charlton A, Fischer K, Fick G, Smith EE, Ismail Z (2023) Validating the
606	[יין	Mild Behavioral Impairment Checklist in a Cognitive Clinic: Comparisons With the
607		Neuropsychiatric Inventory Questionnaire. J Geriatr Psychiatry Neurol 36, 107-120.
608	[75]	Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns
		Light S, Hunney J, Sommeriau A, Annes D, Danard C, Daner C, Drayne C, Durns
MUM.	[/5]	
609 610	[/3]	A, Cohen-Mansfield J, Cooper C (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. <i>The Lancet</i> 396 , 413-446.

It is made available under a CC-BY-NC-ND 4.0 International license .

612 TABLES

613

	Analysis 1*	Analysis 2*	Analysis 3*	Analysis 4*
n	11277	10535	1567	11921
First-Visit Age	77 7 (9 9) 50 0 104 0	72 7 (9 9) 50 0 101 0	72.2(9.9) 50.0 101	72 0 (9 9) 50 0 104
(Years)	72.7 (8.8), 50.0-104.0	72.7 (8.8), 50.0-101.0	72.2 (8.8), 50.0-101	72.9 (8.8), 50.0-104
Females	6658 (59.0)	6412 (60.9)	785 (50.1)	6991 (58.6)
Education (Years)	15.7 (3.1), 0-29.0	15.7 (3.2), 0-29.0	15.4 (3.3), 0-30.0	15.7 (3.1), 0-29.0
Cognitive Status				
CN	8579 (76.1)	8375 (79.5)	797 (50.9)	8628 (72.4)
MCI	2698 (23.9)	2160 (20.5)	770 (49.1)	3293 (27.6)
Race: White	8721 (77.3)	8063 (76.5)	1260 (80.4)	9269 (77.8)
Predictor				
Characteristics				
MBI	1562 (13.9)	-	707 (45.1)	1902 (16.0)
No MBI	9715 (86.1)	-	860 (54.9)	10019 (84.0)
SD	-	820 (7.8)	-	
No SD	-	9715 (92.2)	-	

Note. *Analysis 1: Baseline MBI and incident sleep disturbance, Analysis 2: Baseline sleep disturbance and incident MBI, Analysis 3: Baseline MBI and incident dementia within those with sleep disturbance. Analysis 4: baseline MBI and incident dementia in those without sleep disturbance. All values for continuous variables are shown in mean (SD), range. Values were rounded to one decimal place where appropriate. Categorical variables are shown as n (%). Participants missing data in any of the variables were excluded from descriptive statistical analysis.

Abbreviations: MBI, mild behavioral impairment; CN, cognitively normal; MCI, mild cognitive impairment; SD, sleep disturbance 614

It is made available under a CC-BY-NC-ND 4.0 International license .

Analysis 1		Total (n=11277)	MBI (n=1562)	No MBI (n=9715)	р
n		11277	1562	9715	
First-Visit Age (Years)		72.7 (8.8), 50-104	72.8 (8.5), 50-104	72.7 (8.8), 50-101	0.501 ^w
Females		6658 (59.0)	705 (45.1)	5953 (61.3)	< 0.001
Education (Years)		15.7 (3.1), 0-29	15.7 (3.2), 1-29	15.7 (3.0), 0-29	0.869 ^w
Cognitive Diagnosis					< 0.001 °
(CN	8579 (76.1)	768 (49.2)	7811 (80.4)	
Ν	1CI	2698 (23.9)	794 (50.8)	1904 (19.6)	
Race: White*		8721 (77.3)	1301 (83.3)	7420 (76.4)	< 0.001
Analysis 2		Total (n=10535)	SD Present (n=820)	SD Absent (n=9715)	р
First-Visit Age (Years)	<u> </u>	72.7 (8.8), 50-101	72.2 (8.8), 50-96	72.7 (8.8), 50-101	0.106 ^w
Females		6412 (60.9)	459 (56.0)	5953 (61.3)	0.003 °
Education (Years)		15.7 (3.2), 0-29	15.5 (3.2), 0-25	15.7 (3.0), 0-29	0.054 ^w
Cognitive Diagnosis					< 0.001 °
(CN	8375 (79.5)	564 (68.8)	7811 (80.4)	
N	1CI	2160 (20.5)	256 (31.2)	1904 (19.6)	
Race: White*		8063 (76.5)	643 (78.4)	7420 (76.4)	0.115°
Analysis 3	-	Total (n=1567)	MBI Present (n=707)	MBI Absent (n=860)	р
First-Visit Age (Years)		72.2 (8.8), 50-101	72.2 (8.8), 50-101	72.3 (8.8), 50-96	0.877 ^w
Females		785 (50.1)	307 (43.4)	478 (55.6)	< 0.001
Education (Years)		15.4 (3.3), 0-30	15.1 (3.5), 0-30	15.6 (3.2), 0-25	0.017 ^w
Cognitive Diagnosis					< 0.001
(CN	797 (50.9)	233 (33.0)	564 (65.6)	
N	1CI	770 (49.1)	474 (67.0)	296 (34.4)	
Race: White*		1260 (80.4)	581 (82.2)	679 (79.0)	0.008 °
Analysis 4		Total (n=11921)	MBI Present (n=1902)	MBI Absent (n=10019)	р
First-Visit Age (Years)		72.9 (8.8), 50-104	73.1 (8.6), 50-104	72.8 (8.8), 50-101	0.089 ^w
Females		6991 (58.6)	871 (45.8)	6120 (61.1)	< 0.001
Education (Years)		15.7 (3.1), 0-29	15.6 (3.2), 1-29	15.7 (3.0), 0-29	0.218 ^w
Cognitive Diagnosis					< 0.001
(CN	8628 (72.4)	783 (41.2)	7845 (78.3)	
M	1CI	3293 (27.6)	1119 (58.8)	2174 (21.7)	

Note: All values for continuous variables are shown in mean (standard deviation). Values were rounded to one decimal place where appropriate, except for p-values which were rounded to three decimal places. Categorical variables are shown as n (%). Participants missing data for any of the variables were excluded from descriptive statistical analysis. Analysis (1): baseline mild behavioral impairment (MBI) and incident sleep disturbance (SD); (2) baseline SD and incident MBI; (3) baseline MBI in those with SD and incident dementia; (4) baseline MBI in those without SD and incident dementia

*Non-white races: Black, First Nations American/Alaskan, Native Hawaiian/Other Pacific Islander, Asian or Other. w – Wilcoxon Rank Sum (Mann-Whitney) Test; c – Chi-Squared Test

It is made available under a CC-BY-NC-ND 4.0 International license .

627

Table 3. Multivariable Cox regression models for the association between baseline MBI or sleep disturbance with incident					
sleep disturbance, MBI or dementia using MBI, SD and cognitive diagnosis as time-dependent variables					
		050/ 01			

Exposure Variable	Outcome Variable	HR	95% CI	р
MBI	Sleep Disturbance	3.04	2.77-3.33	< 0.001
Sleep disturbance	MBI	1.52	1.28-1.80	< 0.001
MBI status in those with sleep disturbance	Dementia	2.20	1.91-2.53	< 0.001
MBI status in those without sleep disturbance	Dementia	1.92	1.81-2.03	< 0.001


Note. Associations were tested using multivariable Cox regression models, adjusted for first-visit age, sex, years of education, cognitive diagnosis (CN/MCI), and race. Both MBI status and sleep disturbance were dichotomized. The false rate discovery method was used to adjust *p* values for multiple comparisons.

Abbreviations: MBI, mild behavioral impairment; CN, cognitively normal; MCI, mild cognitive impairment; HR, hazard ratio; CI, confidence interval

	confidence interval
628 629	
630	
631	
632	
633	
634	
635	
636	
637	
638	
639	
640	
641	
642	
643	
644	
645	
646	

It is made available under a CC-BY-NC-ND 4.0 International license .

647 FIGURES



649 Figure 1. Participant Flow Diagram. Analysis 1 examined whether baseline MBI was

associated with incident sleep disturbance. Analysis 2 examined whether baseline sleep

disturbance was associated with incident MBI. Analysis 3 explored whether baseline MBI was

associated with dementia in those with sleep disturbance. Analysis 4 explored whether baseline

653 MBI was associated with dementia in those without sleep disturbance. Abbreviations: NPI-Q,

654 Neuropsychiatric Inventory Questionnaire; MBI, mild behavioral impairment; SD, sleep

655 disturbance

656

657

658

659

660

661


662

...

663

664

It is made available under a CC-BY-NC-ND 4.0 International license .



665

Figure 2. Kaplan-Meier Survival Curves up to 12 years for (A) sleep disturbance-free survival based on MBI status (n = 11277); (B) MBI-free survival based on sleep disturbance (n = 10535); (C) dementia-free survival based MBI with concurrent sleep disturbance (n = 1567); (D) dementia-free survival based MBI without concurrent sleep disturbance (n = 11921).